These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35939887)

  • 1. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
    Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
    Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How is the Ph-like signature being incorporated into ALL therapy?
    Maese L; Tasian SK; Raetz EA
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):222-228. PubMed ID: 29050695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
    Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
    Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
    Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
    Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology of Philadelphia chromosome-like ALL.
    Roberts KG
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
    Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of the JAK-STAT Pathway in Childhood B-Cell Acute Lymphoblastic Leukemia.
    Ziętara KJ; Wróblewska K; Zajączkowska M; Taczała J; Lejman M
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
    Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
    J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
    Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
    Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
    Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why and how to treat Ph-like ALL?
    Roberts KG
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Philadelphia chromosome-like acute lymphoblastic leukemia.
    Tasian SK; Loh ML; Hunger SP
    Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
    Pui CH; Roberts KG; Yang JJ; Mullighan CG
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential role of ruxolitinib in leukemia.
    Naqvi K; Verstovsek S; Kantarjian H; Ravandi F
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1159-66. PubMed ID: 21635221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
    Wells J; Jain N; Konopleva M
    Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome-like Relapsed/Refractory acute lymphoblastic leukemia.
    Bayram N; Yaman Y; Özdilli K; Telhan L; Nepesov S; Bilgen H; Elli M; Behar SS; Anak S
    Pediatr Transplant; 2021 Jun; 25(4):e14024. PubMed ID: 33860589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
    Appelmann I; Rillahan CD; de Stanchina E; Carbonetti G; Chen C; Lowe SW; Sherr CJ
    Blood; 2015 Feb; 125(9):1444-51. PubMed ID: 25499760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
    Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
    N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.